New drug targets rare Cancer's genetic weakness

NCT ID NCT06118086

Recruiting now Disease control Sponsor: Remix Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called REM-422 in people with advanced adenoid cystic carcinoma (ACC), a rare cancer of the glands. The drug works by breaking down a specific genetic message (MYB mRNA) that helps the cancer grow. The trial will enroll 125 participants to see if the drug is safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REM-422 (a drug that breaks down MYB mRNA to reduce tumor growth)
What this could lead to: If successful, this could provide a new treatment option for people with advanced adenoid cystic carcinoma, a rare cancer with few effective therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not prove effective or safe enough for broader use. Side effects are unknown at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOID CYSTIC CARCINOMA METASTATIC ADENOID CYSTIC CARCINOMA RECURRENT ADENOID CYSTIC CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Centre Antoine Lacassagne
RECRUITING

Nice, 06189, France
Dana Farber Cancer Research Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Institut de Cancerologie Gustave-Roussy
RECRUITING

Villejuif, 94805, France
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
University of California San Francisco Helen Diller Comprehensive Cancer Center
RECRUITING

San Francisco, California, 94143, United States
University of Michigan Rogel Cancer Center
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.